Drugs / RAGIFILIMAB
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04470024 | Aug 2021 → Dec 2027 expected | head and neck cancer | Providence Health & Services | Active not recruiting | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT03277352 | Nov 2017 → Jul 2020 | metastatic malignant neoplasm | Incyte Corporation | Terminated | No outcome recorded |
| Phase 1/2 | NCT03126110 | Apr 2017 → Nov 2021 | metastatic malignant neoplasm | Incyte Corporation | Completed | No outcome recorded |
| Phase 1/2 | NCT02697591 | Jun 2016 → Dec 2019 | metastatic malignant neoplasm | Incyte Corporation | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT05359692 | Mar 2023 → Apr 2024 | head and neck squamous cell carcinoma | Incyte Corporation | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT04225039 | Jun 2020 → Sep 2022 overdue | glioblastoma | University of Pennsylvania | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03088059 | Nov 2017 → Jun 2025 | head and neck squamous cell carcinoma | European Organisation for Research and Treatment of Cancer - EORTC | Unknown | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RAGIFILIMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594558 ↗ |
| Known as | AGEN-1876 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594558 ↗ |
| Known as | CM-701 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594558 ↗ |
| Known as | INCAGN01876 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03088059 ↗ |
| Action | Activate | “Glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR) agonism in T cells” PMID 40711469 ↗ Oct 20251“Tumor necrosis factor receptor superfamily member 18 agonist” CHEMBL4594558 ↗ |
| Modality | Monoclonal antibody | “INCAGN01876, a humanized GITR-targeting agonistic mAb” PMID 40711469 ↗ Oct 2025 |
| Route | Intravenous | “Participants received intravenous (IV) infusion of study drug” NCT02697591 ↗ |
| Target | TNFRSF18 | “Tumor necrosis factor receptor superfamily member 18 agonist” CHEMBL4594558 ↗ |